Teva Pharmaceutical Industries Limited (NYSE:TEVA) had its price target lowered by equities researchers at Jefferies Group LLC from $21.00 to $18.50 in a research report issued on Tuesday. The brokerage presently has a “hold” rating on the stock. Jefferies Group LLC’s price objective suggests a potential downside of 1.91% from the company’s previous close.

TEVA has been the topic of several other reports. Credit Suisse Group set a $39.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “buy” rating in a research note on Thursday, August 3rd. Cantor Fitzgerald set a $31.00 target price on Teva Pharmaceutical Industries Limited and gave the company a “hold” rating in a research note on Thursday, June 22nd. Vetr raised Teva Pharmaceutical Industries Limited from a “hold” rating to a “buy” rating and set a $34.17 target price on the stock in a research note on Monday, July 24th. Zacks Investment Research raised Teva Pharmaceutical Industries Limited from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. Finally, BidaskClub cut Teva Pharmaceutical Industries Limited from a “hold” rating to a “sell” rating in a research note on Tuesday, August 8th. Five research analysts have rated the stock with a sell rating, nineteen have assigned a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $32.65.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 18.86 on Tuesday. Teva Pharmaceutical Industries Limited has a one year low of $15.22 and a one year high of $52.66. The company’s market capitalization is $19.16 billion. The company has a 50 day moving average price of $20.22 and a 200-day moving average price of $28.82.

Teva Pharmaceutical Industries Limited (NYSE:TEVA) last posted its earnings results on Thursday, August 3rd. The company reported $0.99 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.06 by ($0.07). Teva Pharmaceutical Industries Limited had a negative net margin of 25.18% and a positive return on equity of 15.96%. The business had revenue of $5.69 billion for the quarter, compared to analysts’ expectations of $5.72 billion. During the same period last year, the firm posted $1.25 earnings per share. Teva Pharmaceutical Industries Limited’s quarterly revenue was up 12.9% on a year-over-year basis. Analysts expect that Teva Pharmaceutical Industries Limited will post $4.32 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Jefferies Group LLC Lowers Teva Pharmaceutical Industries Limited (TEVA) Price Target to $18.50” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/14/jefferies-group-llc-lowers-teva-pharmaceutical-industries-limited-teva-price-target-to-18-50.html.

Several hedge funds have recently bought and sold shares of TEVA. San Francisco Sentry Investment Group CA purchased a new stake in Teva Pharmaceutical Industries Limited during the second quarter valued at $106,000. Bronfman E.L. Rothschild L.P. increased its position in Teva Pharmaceutical Industries Limited by 7.8% during the first quarter. Bronfman E.L. Rothschild L.P. now owns 3,617 shares of the company’s stock valued at $116,000 after acquiring an additional 261 shares during the last quarter. Kistler Tiffany Companies LLC increased its position in Teva Pharmaceutical Industries Limited by 74.7% during the second quarter. Kistler Tiffany Companies LLC now owns 3,673 shares of the company’s stock valued at $122,000 after acquiring an additional 1,571 shares during the last quarter. FNY Managed Accounts LLC purchased a new stake in Teva Pharmaceutical Industries Limited during the first quarter valued at $123,000. Finally, Sterling Investment Advisors Ltd. increased its position in Teva Pharmaceutical Industries Limited by 2.6% during the first quarter. Sterling Investment Advisors Ltd. now owns 3,900 shares of the company’s stock valued at $125,000 after acquiring an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 56.87% of the company’s stock.

About Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

Analyst Recommendations for Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Receive News & Stock Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related stocks with our FREE daily email newsletter.